ReviewInternational journal of breast cancer2015
C-Reactive Protein and Breast Cancer: New Insights from Old Molecule.
Review in International journal of breast cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 4 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- Effects of exercise on inflammation in female survivors of nonmetastatic breast cancer: a systematic review and meta-analysis.Journal of the National Cancer Institute · 2025Pooled it
- Prognostic Role of Pretreatment C-Reactive Protein to Albumin Ratio in Urological Cancers: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Pooled it
- C-reactive protein to albumin ratio predicts the outcome in renal cell carcinoma: A meta-analysis.PloS one · 2019Pooled it
- A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Trial
- Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up.Molecular oncology · 2017Trial
- Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- A novel inflammation and tumor marker-based prognostic score, neutrophil-lymphocyte ratio-C-reactive protein-Ca19-9, in metastatic gastric cancer.Oncology letters · 2026Article
- The Role of Proinflammatory Biomarkers in Oral Cancer Pathophysiology.Advances in experimental medicine and biology · 2026Review
- Preoperative C-reactive protein-to-albumin ratio as a prognostic marker of histopathological characteristics and survival outcomes following radical cystectomy.Frontiers in oncology · 2026Article
- Inflammatory and Nutritional Biomarkers Predict Response to Neoadjuvant Dual Anti-HER2 Therapy in HER2-Positive Breast Cancer: A Retrospective Cohort Study.Cancer management and research · 2026Article
- Serum Hepcidin Levels in Breast Cancer Patients: Investigating the Correlation to Tumor Stage-A Cross-Sectional Study.Health science reports · 2025Article
- Relationship between albumin-globulin ratio and prostate-specific antigen: a cross-sectional study based on NHANES 2003-2010.BMC urology · 2025Article
- C-Reactive Protein in Immune Checkpoint Inhibitor-Associated Colitis: A Scoping Review of Evidence and Knowledge Gaps.Cancer management and research · 2025Review
- Article
- Associations of lifestyle characteristics with circulating immune markers in the general population based on NHANES 1999 to 2014.Scientific reports · 2024Article
- The evaluation of the inflammatory status and systemic antioxidant-oxidant balance of women with breast cancer during adjuvant chemotherapy.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Article
- C-Reactive Protein Signaling Pathways in Tumor Progression.Biomolecules & therapeutics · 2023Review
- Long-term effects of aromatase inhibitors on body mass index among postmenopausal breast cancer survivors in Africa: observational cohort study.BMC research notes · 2023Observational
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently an association between breast cancer and inflammation has emerged as the seventh hallmark of cancer. Chronic inflammation is a key contributor in the development and progression of carcinogenesis. Inflammatory pathways play an important role in the causation of breast cancer. C-reactive protein (CRP) an acute-phase reactant inflammatory protein is synthesized in hepatocytes in response to cytokines that are released from leucocytes within the tumor microenvironment. Several epidemiological studies appraised an association of CRP with breast cancer risk with inconsistent findings. Elevated levels at the time of diagnosis of breast cancer indicate aggressiveness of the tumor. CRP is also a well-established independent prognostic marker. Breast cancer survivors with the state of chronic inflammation are at risk of recurrence and metabolic disturbances. CRP lowering agents along with chemotherapeutic drugs will improve the survival of breast cancer patients. Also, it is a risk predictor for subsequent cardiotoxicity in patients receiving chemotherapy. The present review is aimed at elucidating the role of C-reactive protein, as an inflammatory risk marker and prognostic predictor of breast cancer. It also focuses on conflicting views on the role of CRP in breast cancer and its impact on therapeutic interventions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.